glasdegib (Daurismo) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
PF-04449913 is a potent and selective inhibitor of the Hh signaling pathway through binding to the target, smoothened. PF-04449913 inhibits Hh signaling in vitro and has demonstrated significant antitumor activity in vivo. In the clinic, PF-04449913 is being evaluated both in hematological and solid malignancies, with a phase II trial currently underway in both fit and unfit patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Treatment-related adverse-events were nausea, dizziness, somnolence, QT prolongation and pruritus. Based on pre-clinical assessments, CYP3A4 is believed to be primarily involved in the metabolism of PF-04449913 that is why PF-04449913 plasma exposures and peak concentrations were increased following concurrent administration of ketoconazole (CYP3A4 inhibitor).   NCATS

  • SMILES: CN1CC[C@H](C[C@@H]1C2=NC3=C(N2)C=CC=C3)NC(=O)NC4=CC=C(C=C4)C#N
  • InChIKey: SFNSLLSYNZWZQG-VQIMIIECSA-N
  • Mol. Mass: 374.439
  • ALogP: 3.39
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$205.4582 - $563.2743
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-(2-(1h-benzo(d)imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea | glasdegib | glasdegib (pf-04449913) | pf-04449913 | pf-4449913

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue